Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Pike is active.

Publication


Featured researches published by Andrew Pike.


Drug Metabolism and Disposition | 2006

RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708

John R. Atack; Andrew Pike; Ashley Clarke; Susan M. Cook; Bindi Sohal; Ruth M. McKernan; Gerard R. Dawson

The pharmacokinetic and pharmacodynamic (i.e., receptor occupancy) properties of L-655,708, a compound with selectivity for α5-over α1-, α2-, and α3-containing GABAA receptors, were examined in rats with the aim of developing a formulation that would give sustained (up to 6 h) and selective occupancy of α5-containing GABAA receptors suitable for behavioral studies. Standard rat pharmacokinetic analyses showed that L-655,708 has a relatively short half-life with kinetics in the brain mirroring those in the plasma. In vivo binding experiments showed that plasma concentrations of around 100 ng/ml gave relatively selective in vivo occupancy of rat brain α5-versus α1-, α2-, and α3-containing GABAA receptors. Therefore, this plasma concentration was chosen as a target to achieve relatively selective occupancy of α5-containing receptors using s.c. implantations of L-655,708 (0.4, 1.5, or 2.0 mg) formulated into tablets of various size (20 or 60 mg) containing different amounts of L-655,708 and combinations of low and high viscosity hydroxypropyl methylcellulose (LV- and HV-HPMC). The optimum formulation, 1.5 mg of L-655,708 compressed into a 60-mg tablet with 100% HV-HPMC, resulted in relatively constant plasma concentrations being maintained for at least 6 h with very little difference between Cmax concentrations (125–150 ng/ml) and plateau concentrations (100–125 ng/ml). In vivo binding experiments confirmed the selective occupancy of rat brain α5-over α1-, α2-, and α3-containing GABAA receptors.


ACS Medicinal Chemistry Letters | 2010

Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.

Wesley Peter Blackaby; Richard T. Lewis; Joanne Thomson; Andrew Jennings; Simon Charles Goodacre; Leslie J. Street; Angus Murray Macleod; Andrew Pike; Suzanne Wood; Steve Thomas; Terry A. Brown; Alison J. Smith; Gopalan V. Pillai; Sarah Almond; Martin R. Guscott; H. Donald Burns; Wai-si Eng; Christine Ryan; Jacquelynn J. Cook; Terence G. Hamill

Amalgamation of the structure-activity relationship of two series of GlyT1 inhibitors developed at Merck led to the discovery of a clinical candidate, compound 16 (DCCCyB), which demonstrated excellent in vivo occupancy of GlyT1 transporters in rhesus monkey as determined by displacement of a PET tracer ligand.


Journal of Medicinal Chemistry | 1984

Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity

Charles David Jones; Mary G. Jevnikar; Andrew Pike; Mary Kathleen Peters; Larry John Black; Allen R. Thompson; Julie F. Falcone; James A. Clemens


Journal of Pharmacology and Experimental Therapeutics | 2005

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

John R. Atack; Keith A. Wafford; Spencer J. Tye; Susan M. Cook; Bindi Sohal; Andrew Pike; Cyrille Sur; David Melillo; Linda J. Bristow; Fran Bromidge; Ian Ragan; Julie Kerby; Les Street; Robert W. Carling; José L. Castro; Paul Whiting; Gerard R. Dawson; Ruth M. McKernan


Journal of Medicinal Chemistry | 1992

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines

Per Sauerberg; Preben H. Olesen; Susanne Nielsen; Svend Treppendahl; Malcolm J. Sheardown; Tage Honore; C.H. Mitch; J.S. Ward; Andrew Pike


Journal of Medicinal Chemistry | 1999

Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.

Monique B. van Niel; Ian Collins; Margaret S. Beer; Howard B. Broughton; Susan K. F. Cheng; Simon Charles Goodacre; Anne Heald; Karen L Locker; Angus Murray Macleod; Denise Morrison; Christopher Richard Moyes; Desmond O'Connor; Andrew Pike; Michael Rowley; Michael Geoffrey Neil Russell; Balbinder Sohal; Steven Thomas; Hugh M. Verrier; and Alan P. Watt; José L. Castro


Journal of Medicinal Chemistry | 2006

Imidazo[1,2-a]pyrimidines as Functionally Selective and Orally Bioavailable GABAAα2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Simon Charles Goodacre; Leslie J. Street; David James Hallett; James Michael Crawforth; Sarah Kelly; Andrew Pate Owens; Wesley Peter Blackaby; Richard T. Lewis; Joanna Stanley; Alison J. Smith; Pushpinder Ferris; Bindi Sohal; Susan M. Cook; Andrew Pike; Nicola Brown; Keith A. Wafford; George R. Marshall; José L. Castro; John R. Atack


Journal of Medicinal Chemistry | 2002

3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels

Ian Collins; Christopher Richard Moyes; William B Davey; Michael Rowley; Frances A. Bromidge; Kathleen Quirk; John R. Atack; Ruth M. McKernan; Sally-Ann Thompson; Keith A. Wafford; Gerard R. Dawson; Andrew Pike; Bindi Sohal; Nancy N. Tsou; Richard G. Ball; José L. Castro


Journal of Medicinal Chemistry | 1993

Nonsteroidal inhibitors of human type I steroid 5-.alpha.-reductase

Charles David Jones; James E. Audia; David Ernest Lawhorn; Loretta Ames Mcquaid; Blake Lee Neubauer; Andrew Pike; Pamela A. Pennington; Nancy B. Stamm; Richard E. Toomey; Kenneth Steven Hirsch


Journal of Medicinal Chemistry | 2004

Synthesis and Biological Evaluation of 3-Heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and Analogues as Subtype-Selective Inverse Agonists for the GABAAα5 Benzodiazepine Binding Site

Leslie J. Street; Francine Sternfeld; Richard Alexander Jelley; Austin John Reeve; Robert W. Carling; Kevin William Moore; Ruth M. McKernan; Bindi Sohal; Susan M. Cook; Andrew Pike; Gerard R. Dawson; Frances A. Bromidge; Keith A. Wafford; Guy R. Seabrook; George R. Marshall; Goplan V. Pillai; José L. Castro; and John R. Atack; Angus Murray Macleod

Collaboration


Dive into the Andrew Pike's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge